Thymosin Alpha-1
Thymosin alpha-1 is a 28-amino-acid thymic peptide (marketed outside the U.S. as thymalfasin/Zadaxin) that activates dendritic cells through Toll-like receptor pathways to modulate T-cell immunity, and has been studied in human trials for hepatitis B, cancer adjuvant therapy, sepsis, and as a vaccine-response enhancer.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Thymosin alpha-1 is generated by cleavage of prothymosin alpha and acts primarily on dendritic cells (DCs). It engages Toll-like receptor (TLR2 and TLR9)/MyD88-dependent signaling: TLR9/MyD88 activation in plasmacytoid DCs triggers interferon regulatory factor 7 (IRF7) and drives IFN-alpha/IFN-gamma-dependent antiviral responses, while TLR2-dependent signaling in myeloid DCs primes Th1-type antifungal resistance. It also induces indoleamine 2,3-dioxygenase (IDO) activity in DCs, a pathway linked to immune tolerance, giving the peptide a dual role in both stimulating and regulating immune responses depending on context.
Typical results seen in research
Thymosin alpha-1 has one of the larger human evidence bases among thymic peptides. A randomized trial in postradiotherapy lung cancer patients showed improved T-cell reconstitution and function versus placebo. More recent clinical literature describes improved overall survival when used as an adjuvant in resectable non-small-cell lung cancer and liver cancer, reduced chemoradiation-induced lymphopenia, and use as an immune modulator during SARS and COVID-19 in China; a large narrative review claims safety and efficacy across more than 30 trials and 11,000+ subjects, though that review argues against a 2023 FDA restriction and was published in a lower-tier journal, so its conclusions should be weighed cautiously alongside the primary trial literature.
How it’s commonly used
In clinical and research use outside the United States (where it is marketed as thymalfasin/Zadaxin), thymosin alpha-1 is administered by subcutaneous injection, typically as part of a defined treatment course for conditions such as chronic hepatitis B or as a cancer-therapy adjuvant.
- Annals of the New York Academy of Sciences · 2007 Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance
- Vitamins and Hormones · 2016 Immune Modulation with Thymosin Alpha 1 Treatment
- Journal of Biological Response Modifiers · 1985 A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer
- International Immunopharmacology · 2023 Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era
- Alternative Therapies in Health and Medicine · 2024 Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
- Review Details How Thymosin Alpha-1 Supports Immune Function as the Body Ages —
- Meta-Analysis Finds Thymosin Alpha-1 Eases Immune Complications in Severe Pancreatitis —